Polygenic Score (PGS) ID: PGS000010

Predicted Trait
Reported Trait Coronary heart disease
Mapped Trait(s) coronary artery disease (EFO_0001645)
Released in PGS Catalog: Oct. 14, 2019
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name GRS27
Development Method
Name Genome-wide significant variants
Parameters NR
Variants
Original Genome Build NR
Number of Variants 27
Effect Weight Type NR
PGS Source
PGS Catalog Publication (PGP) ID PGP000003
Citation (link to publication) Mega JL et al. Lancet (2015)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
86,995 individuals (100%)
PGS Evaluation
European: 100%
6 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST000998
[
  • 22,233 cases
  • , 64,762 controls
]
 European 12 cohorts
  • ADVANCE
  • ,AtheroRemo
  • ,CADomics
  • ,CHARGE
  • ,GerMIFS
  • ,LURIC
  • ,MIGen
  • ,MedSTAR
  • ,OHGS
  • ,PennCATH
  • ,WTCCC
  • ,deCODE

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM000014 PSS000008|
European Ancestry|
42,998 individuals
 PGP000003 |
Mega JL et al. Lancet (2015)
 Reported Trait: Coronary heart disease HR: 1.21 [1.17, 1.26] — — age, sex, diabetes status, smoking, race, family history of coronary heart disease, HDL cholesterol, LDL cholesterol, and hypertension Meta-analysis of sub-cohort effect sizes
PPM000015 PSS000009|
European Ancestry|
4,877 individuals
 PGP000003 |
Mega JL et al. Lancet (2015)
 Reported Trait: Coronary heart disease HR: 1.14 [1.02, 1.28] — — age, sex, diabetes status, smoking, race, family history of coronary heart disease, HDL cholesterol, LDL cholesterol, and hypertension Meta-analysis of sub-cohort effect sizes
PPM000017 PSS000010|
European Ancestry|
23,595 individuals
 PGP000004 |
Tada H et al. Eur Heart J (2015)
|Ext.		 Reported Trait: Incident coronary heart disease HR: 1.2 [1.15, 1.25] — — age, sex, systolic blood pressure, hypertension treatment, smoking, apoB, apoA-I, prevalent diabetes —
PPM000019 PSS000012|
European Ancestry|
12,676 individuals
 PGP000005 |
Abraham G et al. Eur Heart J (2016)
|Ext.		 Reported Trait: Incident coronary artery disease HR: 1.21 [1.12, 1.3] — — — —
PPM000021 PSS000011|
European Ancestry|
3,406 individuals
 PGP000005 |
Abraham G et al. Eur Heart J (2016)
|Ext.		 Reported Trait: Incident coronary artery disease HR: 1.2 [1.07, 1.26] — — — —
PPM012951 PSS009630|
European Ancestry|
4,932 individuals
 PGP000306 |
Thompson PL et al. BMC Cardiovasc Disord (2022)
|Ext.		 Reported Trait: Reccurent cardiovascular event (coronary heart disease death, non-fatal myocardial infraction, unstable angina pectoris, coronary artery bypass graft and Percutaneous coronary intervention) — C-index: 0.7 NRI (GRS-added vs. baseline model): 0.097 Hypertension, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, diabetes, sex, age, current smoking Basline model C-index = 0.69

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000008 Coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention —
[
  • 149 cases
  • , 6,829 controls
]
,
79.7 % Male samples
 — European — ASCOT Primary prevention cohorts
PSS000009 Coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention —
[
  • 320 cases
  • , 2,558 controls
]
,
86.1 % Male samples
 — European — CARE_b Secondary prevention cohorts
PSS000009 Coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention —
[
  • 229 cases
  • , 1,770 controls
]
,
77.5 % Male samples
 — European — PROVEIT Secondary prevention cohorts
PSS000010 Incident CHD was defined as coronary revascularization, fatal or nonfatal myocardial infarction, or death due to ischemic heart disease. —
[
  • 2,213 cases
  • , 21,382 controls
]
,
38.03 % Male samples
 — European
(Swedish)		 — MDC Prospective study
PSS000011 The main outcome of interest was incident CHD event before age 75y. We used the definition of CHD as employed by the Framingham study, namely, one of • MI recognized, with diagnostic ECG (FHS event code #1) • MI recognized, without diagnostic ECG, with enzymes and history (#2) • MI recognized, without diagnostic ECG, with autopsy evidence (new event) (#3) • MI unrecognized, silent (#4) • MI unrecognized, not silent (#5) • Angina pectoris (AP), first episode only (#6) • Coronary insufficiency (CI), definite by both history and ECG (#7) • Questionable MI at exam 1 (#8) • Acute MI by autopsy, previously coded as 1 or 2 (#9) • Death, CHD sudden, with 1 hour (#21) • Death, CHD 1–23 hours, non sudden (#22) • Death, CHD 24-47 hours, non sudden (#23) • Death, CHD, 48 hours or more, non sudden (#24) —
[
  • 587 cases
  • , 2,819 controls
]
,
45.0 % Male samples
 — European — FHS FHS Original, FHS Offspring
PSS000012 Coronary heart disease (CHD) was defined as falling into any of the following categories: • I21 or I22 (ICD-10) / 410 (ICD-8/9) as the direct or as a contributing cause of death or I20-I25 (ICD-10) /410-414 (ICD-9) as the underlying cause of death • I21 or I22 (ICD-10) / 410 (ICD-8/9) as the main or secondary diagnosis at hospital discharge. • Coronary bypass surgery or coronary angioplasty at hospital discharge or identified from the Finnish registry of invasive cardiac procedures. —
[
  • 757 cases
  • , 11,919 controls
]
,
46.0 % Male samples
 — European
(Finnish)		 — FINRISK FR92, FR97, FR02
PSS009630 Entry to the trial had required a history of acute coronary syndrome 3–36 months previously, and patients were in the trial for a mean of 36 months. 1558 deaths, 898 cardiovascular deaths, 727 CHD deaths and 375 cancer deaths Mean = 36.0 months
[
  • 898 cases
  • , 4,034 controls
]
,
84.0 % Male samples
 Mean = 60.2 years
Sd = 8.41 years		 European — NR LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease) randomised controlled trial
PSS000008 Coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention — 27,271 individuals,
38.7 % Male samples
 — European
(Swedish)		 — MDC Primary prevention cohorts
PSS000008 Coronary heart disease represented a composite of fatal or non-fatal myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention —
[
  • 108 cases
  • , 8,641 controls
]
,
67.8 % Male samples
 — European — JUPITER Primary prevention cohorts